Method for preparing a polymeric reagent
US-2016324974-A1 · Nov 10, 2016 · US
Oxytocin improves treatment of obstructive sleep apnea
US10166268B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10166268-B2 |
| Application number | US-201515327252-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 2, 2015 |
| Priority date | Jul 25, 2014 |
| Publication date | Jan 1, 2019 |
| Grant date | Jan 1, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure provides methods for treating obstructive sleep apnea (OSA) and OSA induced cardiorespiratory diseases. The disclosure provides, inter alia, methods for treating or alleviating: OSA or OSA induced hypertension, cardiac arrhythmias, myocardial ischemia, sudden cardiac death or stroke, by administering oxytocin. The disclosure further provides methods for improving sleep satisfaction in OSA patients by administering oxytocin.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for treating a patient suffering from obstructive sleep apnea induced hypertension, comprising: intranasally administering to the patient at least 40 International Units (IU) of oxytocin within an hour of the patient falling asleep. 2. The method of claim 1 , wherein the patient is receiving continuous positive airway pressure (CPAP) therapy. 3. The method of claim 1 , wherein the administration of oxytocin reduces the hypertension experienced by the patient. 4. The method of claim 1 , wherein the administration of oxytocin maintains or decreases the heart rate and/or blood pressure of the patient. 5. The method of claim 1 , wherein the administration of oxytocin improves sleep quality in the patient. 6. The method of claim 1 , wherein the administration of oxytocin decreases the number of arousals per hour experienced by the patient during sleep. 7. The method of claim 6 , wherein the administration of oxytocin decreases the number of arousals per hour by at least 10%. 8. The method of claim 1 , wherein the administration of oxytocin decreases the oxygen desaturation experienced by the patient during sleep. 9. The method of claim 1 , wherein the administration of oxytocin decreases the duration of apnea experienced by the patient during sleep. 10. The method of claim 9 , wherein the administration of oxytocin decreases the duration of apnea by at least 10%. 11. A method for treating a patient suffering from obstructive sleep apnea induced hypertension and compromised sleep quality, comprising: intranasally administering to the patient at least 40 International Units (IU) of oxytocin within an hour of the patient falling asleep. 12. The method of claim 11 , wherein the administration of oxytocin reduces the hypertension experienced by the patient. 13. The method of claim 11 , wherein the administration of oxytocin decreases the number of arousals per hour experienced by the patient during sleep. 14. The method of claim 13 , wherein the administration of oxytocin decreases the number of arousals per hour by at least 10%. 15. The method of claim 11 , wherein the administration of oxytocin decreases the oxygen desaturation experienced by the patient during sleep. 16. The method of claim 11 , wherein the administration of oxytocin decreases the duration of apnea experienced by the patient during sleep. 17. The method of claim 11 , wherein the administration of oxytocin decreases the duration of apnea by at least 10%. 18. A method for treating a patient suffering from obstructive sleep apnea induced cardiorespiratory disease, comprising: intranasally administering to the patient at least 40 International Units (IU) of oxytocin within an hour of the patient falling asleep. 19. The method of claim 18 , wherein the obstructive sleep apnea induced cardiorespiratory disease is selected from the group consisting of: hypertension, cardiac arrhythmias, myocardial ischemia, sudden cardiac death, and stroke.
Assignees
Inventors
Classifications
- A61K38/11Primary
Human Necessities · mapped topic
Nose · CPC title
- A61K38/095Primary
Oxytocins; Vasopressins; Related peptides · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10166268B2 cover?
- The present disclosure provides methods for treating obstructive sleep apnea (OSA) and OSA induced cardiorespiratory diseases. The disclosure provides, inter alia, methods for treating or alleviating: OSA or OSA induced hypertension, cardiac arrhythmias, myocardial ischemia, sudden cardiac death or stroke, by administering oxytocin. The disclosure further provides methods for improving sleep sa…
- Who is the assignee on this patent?
- Mendelowitz David, Jain Vivek, Jameson Heather, and 2 more
- What technology area does this patent fall under?
- Primary CPC classification A61K38/11. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).